


RA Treatment Decisions Following First TNFi Failure



ACR GUIDELINE:



Conditional recommendation to switch¹²

Based on very low-certainty* evidence supporting better disease outcomes and treatment persistence with MOA switching

Who may be appropriate to switch?¹



Patients who are primary non-responders, whose disease may be driven by TNF- α -independent mechanisms

It is unlikely these patients will reach treatment targets with a second TNFi, and may have success with another MOA

Who may be appropriate to cycle?¹



Patients who initially had a good TNFi response, but had a later secondary loss of response

Selecting a structurally and/or functionally different TNFi may be successful in these patients

An individual patient's **preferences, lifestyle, comorbidities, and concomitant medications** are also important to consider when selecting a treatment⁹

Consider your patient's reason for first TNFi failure when deciding to switch vs. cycle

ACR, American College of Rheumatology; ACR20, improvement of $\geq 20\%$ in ACR core criteria; LDA, low disease activity; MOA, mechanism of action; RA, rheumatoid arthritis; TNF, tumor necrosis factor; TNFi, TNF inhibitor.

*Very low-certainty evidence supporting greater improvement in disease activity and drug survival among patients switching classes, as determined following a systematic literature search.

1. Johnson KJ et al. *Clin Rheumatol*. 2019;38(11):2967–2976; 2. Souto A et al. *Rheumatology (Oxford)*. 2016;55(3):523–534; 3. Strand V et al. *Rheumatol Ther*. 2017;4(2):489–502; 4. Gottenberg JE et al. *JAMA*. 2016;316(11):1172–1180; 5. Bogas P et al. *Ther Adv Musculoskelet Dis*. 2021;13:1759720X211060910; 6. Wei W et al. *Adv Ther*. 2017;34(8):1936–1952; 7. Monaco C et al. *Int Immunol*. 2015;27(1):55–62; 8. Aaltonen KJ et al. *PLoS One*. 2012;7(1):e30275; 9. Taylor PC et al. *Ther Adv Musculoskelet Dis*. 2022;14:1759720X221114101; 10. Smolen JS et al. *Lancet*. 2016;388:2763–2774; 11. Smolen JS et al. *Ann Rheum Dis*. 2012;71:1671–1679; 12. Fraenkel L et al. *Arthritis Care Res (Hoboken)*. 2021;73(7):924–939.